Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary HUTCHMED (
Adj EPS $8.38 VS. $6.31 Y/Y - Rev $22.97B (est $20.59B) - Zepbound Rev $4.93B (est $4.64B) - Mounjaro Rev $9.9B (est $8.83B) - Sees FY Adj EPS $35.50 To $36.50, Saw $35.50 To $37 - Sees FY Rev. $85.0B To $87.0B, Saw $82.0B To $85.0B - Committed Addl $4.5B To Expand Manufacturing Sites - Raises Year Guidance
Eli Lilly Q2 2026 Earnings
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
() -- Truist Securities revised its model for Eli Lilly (LLY.SW, LLY.F), raising its price target and earnings forecast for the pharmaceutical giant, as analysts anticipate a "beat and raise" second quarter. "We note strong US script growth (Zepbound/ Mounjaro) offset by [slower-than-expected Foundayo growth]. We maint